Increased fertility in bovine species
The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows.
1. A method of increasing the conception rate in one or more cows comprising administering to the cows an effective amount of an immunomodulator composition, wherein the immunomodulator composition comprises: a cationic liposome delivery vehicle, wherein the liposome delivery vehicle comprises one or more pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylanimonium chloride (DOTMA) and cholesterol; N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl) imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol and an isolated bacterially obtained nucleic acid molecule that does not code for an immunogen and has at least 90% sequence identity with the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
2. The method of claim 1 , wherein said nucleic acid molecule comprises at least one immunostimulatory CpG motif and at least one non-immunostimulatory CpG motif.
3. The method of claim 1 , wherein the Liposome delivery vehicle comprises one or more lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.
4. The method of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 1.
5. The method of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 2.
6. The method claim 1 wherein the immunomodulator composition further comprises a biological agent.
7. The method of claim 6 , wherein the biological agent is selected from the group consisting of immune enhancer proteins, immunogens, vaccines, antimicrobials or any combination thereof.
8. The method of claim 1 , wherein the administering is selected from the group consisting of intravenously, intramuscularly, intradermal, intraperitoneal, subcutaneously, by spray-aerosol, orally, intraocularly, intracheally, and intranasal.
9. The method of claim 1 wherein the immunomodulator composition further comprises comprising a pharmaceutically acceptable earner.
10. The method of claim 1 wherein the conception rate in cows increases relative to the conception rate in a control population as measured by a p-value of ≤0.05.